Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CG Oncology (CGON) Operating Expenses (2023 - 2025)

CG Oncology filings provide 3 years of Operating Expenses readings, the most recent being $51.0 million for Q4 2025.

  • On a quarterly basis, Operating Expenses rose 32.51% to $51.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $194.8 million, a 68.23% increase, with the full-year FY2025 number at $194.8 million, up 68.23% from a year prior.
  • Operating Expenses hit $51.0 million in Q4 2025 for CG Oncology, down from $52.8 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $52.8 million in Q3 2025 to a low of $9.9 million in Q1 2023.
  • Median Operating Expenses over the past 3 years was $27.2 million (2024), compared with a mean of $30.5 million.
  • Biggest five-year swings in Operating Expenses: skyrocketed 131.95% in 2024 and later surged 32.51% in 2025.
  • CG Oncology's Operating Expenses stood at $19.4 million in 2023, then soared by 98.93% to $38.5 million in 2024, then skyrocketed by 32.51% to $51.0 million in 2025.
  • The last three reported values for Operating Expenses were $51.0 million (Q4 2025), $52.8 million (Q3 2025), and $48.7 million (Q2 2025) per Business Quant data.